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The role of microRNA-1 (miR-1) has been studied in cardiac and skeletal muscle differentiation. However, it
remains unexplored in vascular smooth muscle cells (SMCs) differentiation. The aim of this study was to un-
cover novel targets of and shed light on the function of miR-1 in the context of embryonic stem cell (ESC)
differentiation of SMCs in vitro. miR-1 expression is steadily increased during differentiation of mouse ESC to
SMCs. Loss-of-function approaches using miR-1 inhibitors uncovered that miR-1 is required for SMC lineage
differentiation in ESC-derived SMC cultures, as evidenced by downregulation of SMC-specific markers and
decrease of derived SMC population. In addition, bioinformatics analysis unveiled a miR-1 binding site on the
Kruppel-like factor 4 (KLF4) 3’ untranslated region (30UTR), in a region that is highly conserved across species.
Consistently, miR-1 mimic reduced KLF4 30UTR luciferase activity, which can be rescued by mutating the miR-1
binding site on the KLF4 30UTR in the reporter construct. Additionally, repression of the miR-1 expression bymiR-
1 inhibitor can reverse KLF4 downregulation during ESC-SMC differentiation, which subsequently inhibits SMC
differentiation. We conclude that miR-1 plays a critical role in the determination of SMC fate during retinoid acid-
induced ESC=SMC differentiation, which may indicate that miR-1 has a role to promote SMC differentiation.
Introduction
The recent discovery ofmicroRNAs (miRs) introduces anovel type of regulatory control over gene expression
during plant and animal development [1,2]. The finding that
some of these miRs are expressed in specific mesoderm and
muscle tissues has rekindled an interest in post-transcrip-
tional regulation during muscle development and pathology
and has raised the question of the role of miRs during this
process. MiRs comprise a large family of *22-nucleotide
single-stranded RNAs that decrease gene expression by
binding to target mRNAs and causing translational repres-
sion. Subsequently, miRs can cause partial or full silencing of
respective target genes. Further, it seems that miRs can form
extensive regulatory networks with a complexity comparable
to that of transcription factors [3,4]. Bioinformatics prediction
tools for miR targets allow us to get a glimpse at the com-
plexity of cross-regulation, multiplicity, and redundancy in
targeting, and also the multilayered nature of potential miR
regulatory networks. Several miRs have been shown to be
involved in skeletal muscle cell, cardiomyocyte, and smooth
muscle cell (SMC) biology [5–10]. Specifically, emerging data
suggest that miR-1 is involved in skeletal muscle cell and
cardiomyocyte differentiation, cardiac hypertrophy and the
maintenance of normal cardiac function [9,11]. However, the
role of miR-1 in SMC differentiation remains unexplored.
Here, we analyzed miR-1 expression and function during
mouse ESC=SMC differentiation and our results define miR-1
as a positive regulator of SMC differentiation through specific
targeting of Kruppel-like factor 4 (KLF4), an antimyogenic
factor [12–16]. Thus, our studies establish miR-1 as a factor to
enhance SMC differentiation.
Methods
Mouse embryonic stem cell=SMC
differentiation system
Dicer= embryonic stem cells (ESCs) (kindly provided by
Dr. Gregory J. Hannon of Cold Spring Harbor Lab) [17] and
wild-type (WT) ESCs (CMTI-1) were routinely expanded and
induced to differentiate into SMCs in vitro treated with
10mM all trans-retinoid acid (RA) following the protocol
described in our previous report [18].
TaqMan miR assay
For measurement of miR expression, specific primers
for miR-1 and U6 (Applied Biosystem) were used. miR-1
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expression was quantified using TaqMan miR assays (Ap-
plied Biosystem) following the manufacturer’s protocol. All
TaqMan miR assays were performed in triplicate. Total RNA
input was normalized based on the threshold cycle (Ct)
values of the U6 assay as an endogenous control. The fold
change was calculated based on delta Ct between endoge-
nous U6 control and miR-1.
Quantitative real time-polymerase chain reaction
Total RNA was extracted by using the RNeasy mini kit
(Qiagen) following previous report [18]. cDNA was synthe-
sized and subjected to polymerase chain reaction (PCR)
amplification with primers specific for mouse SMC genes
and other control genes with 18S RNA as an internal stan-
dard. PCR primers and reaction conditions are described in
Supplementary Table S1 (Supplementary Materials available
online at www.liebertonline.com=scd) [19].
Transient transfection of miR inhibitor or mimic
and infection of adenovirus expressing KLF4
For inhibiting the function of cellular miR-1, a commer-
cially available miR-1 inhibitor or mimic and inhibitor neg-
ative control (NC) or mimic NC (Dharmacon) [20] were used
for transfection. A complex of Lipofectamine 2000 (Invitro-
gen) and 50 nM miR-1 inhibitor=mimic or inhibitor=mimic
NC were prepared according to the manufacturer’s instruc-
tions and previous report [21]. Adenovirus expressing KLF4
(Ad-KLF4, kindly provided by Dr. GK Owens) [14] was used
to infect differentiating ESCs, with adenovirus expressing
green fluorescence protein (Ad-GFP) serving as control.
Immunofluorescence staining and fluorescence-
activated cell sorting analysis
Immunofluorescence staining and fluorescence-activated
cell sorting (FACS) analysis was performed following a pre-
vious report [22]. Briefly, cell pellets were fixed and permea-
bilized using a BD cytofix=cytoperm kit (BD Bioscience) and
incubated overnight with antibodies (anti-a-smooth muscle
actin [a-SMA] antibody from Millipore and anti-smooth
muscle myosin heavy chain [SMMHC] from BTI). Mouse
IgG2a served as isotypic control (Dakocytomation), respec-
tively. Goat anti-mouse IgG Alexa fluor 488 (green) or 594
(Red) served as secondary antibody (Molecular Probes).
Finally, fluorescence was imaged by fluorescence microscopy
(Olympus) and analyzed using the FACSCalibur system
(BD Biosciences) following the user’s guide.
Construction of reporter plasmid
and reporter assays
A construct in which a fragment of the 3’ untranslated re-
gion (3’-UTR) of KLF4 mRNA containing the putative or
mutated (MU) miR-1 binding sequence was used. pMIR-
REPORT vectors (Promega) harboring KLF4 (951 bp) se-
quences withWT (50-ggauggaucuucuaucauuccaa-30, from 286
to 292 bp of the 30 UTR region) or MU (50 ggauggaucuu-
cuaucauCUUGa- 30, with the MU positions indicated by
capital letters and underscore) miR-1 binding sites were
generated by cloning into the SacI andHindIII restriction sites
of pMIR-REPORT, independently. Cloning primers are
shown in Supplementary Table S2. Luciferase activity assays
were performed in 293T cells co-transfected with (1) miR-1
mimic or mimic NC (Dharmacon; 50 nM) and (2) pMIR-
REPORT vectors containing WT or MU miR-1 binding sites
(200 ng), together with Renilla luciferase control reporter
vector [pRL-thymidine kinase (TK)] using Lipofectamine 2000
(Invitrogen). Cells were further grown in Dulbecco’s modified
Eagle’smedium=F12 supplementedwith 10% fetal bovine serum,
and relative luciferase measurements were performed 48h post-
transfection using the dual Luciferase Reporter Assay System
(Promega) by a Luminescence Counter (PerkinElmer). Luciferase
activity of each sample was normalized to the responding thy-
midine kinase (TK) promoter–Renilla-luciferase activity.
miR target search
Target genes for miR-1 were predicted using open-source
software PicTar (http:==pictar.mdc-berlin.de=) and TargetS-
can 4.2 (www.targetscan.org=).
Western blot analysis
Protein samples from cells and tissues were extracted using
the mammalian protein extraction reagent M-Per (Promega)
supplemented with a protease inhibitor cocktail (Roche).
Antibodies against a-SMA (1:3,000; Millipore), SMMHC
(1:2,000; BTI), b-tubulin (1:10,000; Millipore), Myocardin
(MyoCD, 1:1,000; Abcam), and KLF4 (1:500; Abcam) were
used for testing individual protein expression. Im-
munoactivity was observed by the enhanced chemilumines-
cence detection system (Amersham Biosciences) according to
the manufacturer’s instructions.
Statistical analysis
Data were analyzed by analysis and tested for statistical
significance by the Student-Newman-Keuls test using SY-
STAT software (SYSTAT) with values of P< 0.05 considered
to be significant. All experiments were independently re-
peated at least 3 times.
Results
miR-1 is induced during SMC differentiation
from mouse ESCs
SMC differentiated from ESC differentiation with the
treatment of RA, as we showed previously [21] and in Fig. 1A
and Supplementary Fig. S1. miR-1 was quantified in undif-
ferentiated and differentiated cells at different time points by
TaqMan miR assay. As shown in the Fig. 1B, miR-1 was sig-
nificantly upregulated *30-fold in RA-induced SMC differ-
entiation (Fig. 1B) at day 6 and kept increasing with extended
culture times. Expression of several reported SMC-related
miRs analyzed (Supplementary Fig. S2A) showed that miR-21
and miR-145 increased along with SMC differentiation from
ESCs, whereas miR-221 and miR-222 had no significant
change, at least by 3-day induction.
miR-1 is required for mouse ESC=SMC differentiation
To test the hypothesis that miR-1may have an active role as
a positive regulator of SMC differentiation, we blocked miR-1
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expression during ESC=SMC differentiation by transfecting
miR-1 inhibitor into mouse ESCs. Results showed a dramatic
repression of miR-1 upregulation, which was sustained up to
day 8 (Supplementary Fig. S2B). Such inhibitory effect on
miR-1 was specifically targeted on miR-1, with no effect on
other miRs, as determined by TaqMan miR assay (data no
shown). Transfection with miR-1 inhibitor resulted in major
repression of SMC-specific markers, including a-SMA and
SMMHC, as determined by quantitative real time PCR (qRT-
PCR) and Western blotting (Fig. 2A, B). Further, FACS anal-
ysis showed that the efficiency of SMC differentiation from
mouse ESCs was reduced after the introduction of miR-1 in-
hibitor (Fig. 1C, 90.09% 3.12% in the inhibitor NC group vs.
66.24% 5.73% in the miR-1 inhibitor group, n¼ 4, P< 0.05).
FIG. 1. miR-1 is upregulated during
SMC differentiation. (A) Representative
Western blot showed that the pluripotent
gene octamer-binding protein 4 (OCT4)
was downregulated and SMC-specific
markers upregulated dramatically along
with the RA treatment on mouse ESCs at
the indicated days. (B) miR-1 expression
during RA-induced SMCs from ESCs cul-
tured for 0, 3, 6, or 9 days, at which time
miR-1 were measured by TaqMan miR
assay and normalized to U6. Fold changes
are shown with respect to DMSO-treated
cells, where miR-1 levels on day 0 were set
to a value of 1. miR-1, microRNA-1; SMC,
smooth muscle cell; RA, retinoic acid; SMMHC, smooth muscle myosin heavy chain; ESC, embryonic stem cell; a-SMA,
a-smooth muscle actin; DMSO, dimethyl sulfoxide.
FIG. 2. Inhibition of miR-1 represses
SMCdifferentiation. (A, B)Regulation of
SMC differentiation by miR-1 inhibitor.
About 50nM miR-1 inhibitor repressed
expression of SMC-specific markers,
including a-SMA and SMMHC, as evi-
denced by Western-blotting (C).
*P< 0.05. (C) miR-1 inhibitor reduced
the SMC differentiation efficiency deter-
mined by fluorescence-activated cell
sorting. Left panel: Green histogram
represents IgG2a isotype control and red
represents anti-a-SMA of rat aorta SMCs
(RASMCs) as positive control. Right
panel: the proportion of the a-SMA-
positive cells with green and blue
representing inhibitor NC and miR-1
inhibitor, respectively. n¼ 4. PCR, poly-
merase chain reaction; NC, negative
control; FITC, fluorescein isothiocyanate.
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Compared to the inhibitor NC, miR-1 inhibitor slightly in-
creased octamer-binding protein 4 (OCT4) mRNA level;
however, no effect was observed on other germline marker
expression, including NeuroD1, alpha-fetoprotein (AFP), and
GATA binding protein 2 (GATA2) (Supplementary Fig. S2C).
In addition, miR-1 mimic introduction into Dicer= ESCs has
significant beneficial effect in the context of SMC differentia-
tion (Supplementary Fig. S2D). Taken together, the results
indicate that miR-1 upregulation is required for efficient RA-
mediated mouse ESC=SMC differentiation.
miR-1 inhibits KLF4 expression
An inverse relationship between miR-1 expression (Fig. 1B)
and KLF4 protein (Fig. 3A) during mouse ESC=SMC differ-
entiation was unveiled. Consistently, with overexpression of
KLF4 in mouse ESCs infected with an Ad-KLF4 vector (Sup-
plementary Fig. S3), expression of SMC-specific markers, in-
cluding a-SMA and MyoCD, was attenuated (Fig. 3B).
Bioinformatics search for putative miR-1 binding sites within
the KLF4 mRNA revealed that miR-1 is predicted to hybridize
to a seed sequence in the KLF4 30-UTR, which is evolutionarily
conserved among vertebrate species (Fig. 4A). Secondary
structure analysis also showed a favorable minimum free en-
ergy (18.8kcal=mol) in the formation of the miR-1: KLF4
30UTR duplex stem-loop (Supplementary Fig. S4A). Further, a
predicted binding exists between the seed region of miR-1 and
the 30UTR of KLF4, suggesting that miR-1 is involved in
translational repression ofKLF4. To determinewhether KLF4 is
a direct target of miR-1 we cloned a 951-bp fragment of the
KLF4 30 UTR containing the predicted miR-1 target sequence
(50-ggauggaucuucuaucauuccaa-30, from 286 to 292bp of the 30
UTR region) into downstream of the firefly luciferase gene in
the pMIR-Report vector (Promega) (Supplementary Fig. S4B).
Co-transfection of miR-1 with the KLF4 30 UTR reporter re-
sulted in a dose-dependent repression of luciferase activity
(P< 0.05) (Fig. 4B). This was specific to miR-1 binding since the
effect was prevented by mutation of the putative miR-1 com-
plementary seed sequence (Fig. 4B). In addition, miR-1 did not
show binding to KLF2, KLF5, and KLF13 30UTR, evidenced by
individual luciferase activity (Supplementary Fig. S4C). Fur-
ther, KLF4 expressionwas restoredbymiR-1 inhibitor (Fig. 4C),
consistent with the functional prediction that miR-1 binding to
the KLF4 30UTR would lead to KLF4 translational repression.
Taken together, these results strongly support that miR-1
regulates expression of KLF4 at the post-transcriptional level
during mouse ESC=SMC differentiation.
Discussion
Compared to cardiac and skeletal muscle, only a few
miRs, including miR-21 [5,23,24], miR-221 [8,25], miR-145,
and miR-143 [7,10], have been investigated in SMCs, par-
tially due to the limitations in availability of efficient and
reproducible SMC differentiation models. We have recently
developed a simple and highly efficient in vitro model for
RA-induced SMC differentiation from mouse ESC [18]. This
system allows us to explore the potential roles of individual
miRs and miR:target pairs during SMC differentiation in
vitro, and when combined with experimental angioplasty
and transgenic mice models, it provides a powerful tool to
study how they translate to vascular development and dys-
function in vivo. In the study presented here we have iden-
tified the miR-1:KLF4 pair for its ability to positively regulate
mouse ESC=SMC differentiation in in vitro model.
The observation that miR-1 expression was steadily upre-
gulated during mouse ESC=SMC differentiation, whereas the
miR-1 inhibitor partially repressed SMC differentiation, in-
dicated that miR-1 expression, induced by RA treatment via a
still unknownmechanism, canmodulate the differentiation of
SMC in this model. The inhibitor NC was used as the control
for miR-1 inhibitor in parallel. Difference in expression of
a-SMA and SMMHC shown here in the control group maybe
due to (1) the vulnerability of stem cell differentiation to ex-
ogenous transfection; (2) SMMHC is the late-stage and more
selective-SMCmarker, while a-SMA early stage marker in the
category of SMC differentiation. Although dimethyl sulfox-
ide-treated cells also showedmoderate upregulation of miR-1
(5-fold by day 6), this upregulation was not as remarkable as
the one observed in the RA-treated cells, and may result from
a low percentage of spontaneous differentiation of ESCs into
SMCs. Interestingly, miR-1 mimic per se cannot drive SMC
differentiation in the absence of RA treatment, which implies
that miR-1 upregulation is elegantly integrated in harmony
with other regulatory mechanisms operating during RA-
induced SMC differentiation.
We subsequently investigated the possible mechanism
(miR:target pair=s) responsible for miR-1-positive effects on
SMC differentiation in this system. Remarkably, KLF4 was
consistently predicted by 2 algorithms, TargetScan [26] and
PicTar [27]. KLFs are a subclass of evolutionarily conserved
transcription factors [28] and KLF4 expression is associated
with growth arrest and the inhibitory effect of SMC marker
expression [29]. Previous studies have demonstrated that
KLF4 potently represses expression of multiple SMC genes by
FIG. 3. KLF4 attenuates ESC=SMC dif-
ferentiation. (A) Representative Western
blots probing for KLF4 and MyoCD in
ESCs differentiating to SMCs at the indi-
cated days. (B) Mouse ESCs were infected
with adenovirus expressing KLF4 (Ad-
KLF4) and subsequently induced to differ-
entiate into SMCs with RA. The derived
cells were subject to qRT-PCR analysis and
the expression of SMC markers was de-
tected in extracts from cells differentiated
for 6 days. 18sRNA served as internal
control for qRT-PCR. KLF4, Kruppel-like
factor 4; MyoCD, myocardin. *P< 0.05.
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repressing MyoCD levels during phenotypic switching of
SMC in response to vascular injury, transforming growth
factor-b, or platelet-derived growth factor-BB [14–16,30–34].
We observed an inverse relationship in expression be-
tween miR-1 and KLF4 during SMC differentiation from
ESCs and luciferase assays demonstrated that there is a pu-
tative functional binding between mature miR-1 and the
KLF4 30UTR. Further, inhibition of miR-1 expression resulted
in upregulation of KLF4 protein levels. Taken together, these
results indicate that KLF4 is an miR-1 target, mediating its
positive effects in modulation of SMC differentiation.
In summary, the results presented here derived from a
systematic experimental approach that allowed us to identify
novel ‘‘miR:target’’ gene pairs involved in SMC differentia-
tion indicate that miR-1 plays a functional role in positively
modulating SMC differentiation from ESCs. Moreover, miR-
1-mediated inhibition of KLF4 may, in part, account for the
observed effects on SMC differentiation in this study. Further
investigation into the function of miR-1 during SMC differ-
entiation, development, and dysfunction will provide addi-
tional insight on the role of small noncoding RNAs in these
processes and establish miRs as potential therapeutic target
for vascular disease.
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